Vicarious Surgical Toekomstige groei

Future criteriumcontroles 0/6

De winst van Vicarious Surgical zal naar verwachting dalen met 3.8% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 70.3% per jaar. De winst per aandeel zal naar verwachting groeien met 24.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -222.8% zijn.

Belangrijke informatie

-3.8%

Groei van de winst

24.8%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.0%
Inkomstengroei	70.3%
Toekomstig rendement op eigen vermogen	-222.8%
Dekking van analisten	Low
Laatst bijgewerkt	13 Nov 2024

Recente toekomstige groei-updates

Recent updates

Vicarious Surgical: Huge Potential But Low Margin Of Safety To Commercialization

Aug 24

Here's Why We're Watching Vicarious Surgical's (NYSE:RBOT) Cash Burn Situation

Jul 18

Vicarious Surgical: Cash Burn Adds To Downside Risk

May 26

Vicarious Surgical Non-GAAP EPS of -$0.16 beats by $0.02

Feb 13

Vicarious Surgical Non-GAAP EPS of -$0.18 misses by $0.03

Nov 07

Vicarious Surgical Non-GAAP EPS of -$0.16 misses by $0.02

Aug 08

Vectoring In On Vicarious Surgical Inc.

Jun 23

Vicarious Surgical: Developing Minimally Invasive VR Surgical System

Nov 29

Winst- en omzetgroeiprognoses

NYSE:RBOT - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-79	N/A	N/A	3
12/31/2025	N/A	-76	N/A	N/A	3
12/31/2024	N/A	-66	N/A	N/A	3
9/30/2024	N/A	-62	N/A	N/A	N/A
6/30/2024	N/A	-61	-55	-54	N/A
3/31/2024	N/A	-61	-60	-58	N/A
12/31/2023	N/A	-71	-64	-62	N/A
9/30/2023	N/A	-69	-71	-69	N/A
6/30/2023	N/A	-78	-68	-66	N/A
3/31/2023	N/A	-64	-69	-65	N/A
12/31/2022	N/A	5	-67	-61	N/A
9/30/2022	N/A	38	-58	-53	N/A
6/30/2022	N/A	18	-57	-52	N/A
3/31/2022	N/A	13	-47	-44	N/A
12/31/2021	N/A	-35	-35	-33	N/A
9/30/2021	N/A	-61	-28	-27	N/A
6/30/2021	N/A	-19	-17	-16	N/A
3/31/2021	N/A	-15	-14	-14	N/A
12/31/2020	N/A	-13	-12	-12	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat RBOT de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat RBOT de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat RBOT de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat RBOT volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat RBOT volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat RBOT binnen 3 jaar verliesgevend zal zijn.

Vicarious Surgical Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 18% to US$11.17

Price target increased by 21% to US$37.50

Price target decreased by 84% to US$1.13

Price target decreased by 21% to US$7.75

Price target decreased to US$11.80

Recent updates

Price target increased by 18% to US$11.17

New major risk - Share price stability

Vicarious Surgical Inc. to Report Q3, 2024 Results on Nov 12, 2024

Here's Why Vicarious Surgical (NYSE:RBOT) Must Use Its Cash Wisely

Vicarious Surgical Inc. to Report Q2, 2024 Results on Aug 12, 2024

Price target increased by 21% to US$37.50

Vicarious Surgical Inc., Annual General Meeting, Jun 10, 2024

Vicarious Surgical Inc. to Report Q1, 2024 Results on Apr 29, 2024

New major risk - Revenue and earnings growth

Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?

Vicarious Surgical Inc. to Report Q4, 2023 Results on Mar 04, 2024

Vicarious Surgical Inc. Announces Management Changes

Vicarious Surgical Inc. Announces Appointment of Randy Clark as President Effective, January 29, 2024

Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?

Price target decreased by 84% to US$1.13

Vicarious Surgical Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Market cap size

Vicarious Surgical Receives Continued Listing Standard Notice From NYSE

Vicarious Surgical Receives Continued Listing Standard Notice From NYSE

Vicarious Surgical: Huge Potential But Low Margin Of Safety To Commercialization

New minor risk - Share price stability

Here's Why We're Watching Vicarious Surgical's (NYSE:RBOT) Cash Burn Situation

Vicarious Surgical Inc. to Report Q2, 2023 Results on Jul 27, 2023

New minor risk - Insider selling

Co-Founder recently sold US$54k worth of stock

Vicarious Surgical: Cash Burn Adds To Downside Risk

Co-Founder notifies of intention to sell stock

Vicarious Surgical Inc. Announces Promotion of John Mazzola to Chief Operating Officer

Insider recently bought US$153k worth of stock

Investor sentiment deteriorates as stock falls 21%

Insider recently bought US$139k worth of stock

Insider recently bought US$78k worth of stock

Co-Founder recently sold US$65k worth of stock

Co-Founder notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 21% to US$7.75

Insider recently bought US$241k worth of stock

Vicarious Surgical Non-GAAP EPS of -$0.16 beats by $0.02

Investor sentiment improves as stock rises 17%

Vicarious Surgical Inc. to Report Q4, 2022 Results on Feb 13, 2023

Vicarious Surgical Inc. Announces Changes to Board of Directors

Investor sentiment improved over the past week

Vicarious Surgical Completes Public Demonstration of Beta 2 Surgical Robotic System

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Co-Founder recently sold US$74k worth of stock

High number of new and inexperienced directors

Vicarious Surgical Non-GAAP EPS of -$0.18 misses by $0.03

Investor sentiment improved over the past week

Vicarious Surgical Inc. to Report Q3, 2022 Results on Nov 07, 2022

CFO & Treasurer notifies of intention to sell stock

Vicarious Surgical Inc. Announces Changes to Board of Directors

Independent Director recently sold US$54k worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Independent Director recently sold US$87k worth of stock

Vicarious Surgical Non-GAAP EPS of -$0.16 misses by $0.02

Vicarious Surgical Inc. to Report Q2, 2022 Results on Aug 08, 2022

Investor sentiment improved over the past week

Vectoring In On Vicarious Surgical Inc.

Investor sentiment improved over the past week

Independent Director recently sold US$119k worth of stock

Investor sentiment improved over the past week

Independent Director recently sold US$169k worth of stock

High number of new and inexperienced directors

Vicarious Surgical Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$11.80

Vicarious Surgical Inc. to Report Q1, 2022 Results on May 09, 2022

Vicarious Surgical Inc. to Report Q4, 2021 Results on Mar 03, 2022

Vicarious Surgical: Developing Minimally Invasive VR Surgical System